FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 and CRBN, thereby selectively degrading FKBP12.
IC50&Target
Cereblon
FKBP12(F36V)
体外研究
TAG-13 (1-1000 nM; 4 hours; 293FT cells) treatment potently reduces FKBP12-Nluc levels in 293FT cell, indicating the requirement of CRBN for the observed effects.
Treatment of MV4;11 cells expressing BRD4(short)-FKBP12 with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou. dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12.
Western Blot Analysis
Cell Line:
293FT cells
Concentration:
1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time:
4 hours
Result:
Potently reduced FKBP12-Nluc levels in 293FT cell.
体内研究
Following bone marrow engraftment of MV4;11 cells expressing luc-FKBP12F36V in mice, the bioluminescent signal after vehicle or dTAG-13 administration is monitored. A significant, rapid, and durable effect on bioluminescent signal is observed four hours after dTAG-13 administration, indicating effective degradation of luc-FKBP12F36V. Twenty-eight hours following the final treatment, the recovery of cellular bioluminescence to levels comparable between vehicle and dTAG-13 treatment groups is observed.
分子式
C57H68N4O15
分子量
1049.17
CAS号
2064175-41-1
运输条件
Room temperature in continental US; may vary elsewhere.